Ultragenyx to sell FDA priority review voucher for $210M (RARE)

Ultragenyx to sell FDA priority review voucher for $210M (RARE)

Ultragenyx Pharmaceutical (RARE) stock gains as the company inks a $210M deal to sell an FDA priority review voucher tied to recent Genglycos approval. Read more here.

Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.

Ultragenyx agrees to sell voucher for US$210M

Ultragenyx expects US$210M from a voucher sale tied to Genglycos approval, subject to an antitrust waiting period and other closing conditions.

Ultragenyx sells PRV for $210M and still has another voucher it plans to monetize

Ultragenyx Pharmaceutical is selling a priority review voucher to an undisclosed buyer for $210 million, marking one of the richest sales of the speedy-approval tool so far this year. The California ...